Indacaterol, glycopyrronium, and mometasone: Pharmacological interaction and anti-inflammatory profile in hyperresponsive airways.
Acetylcholine
/ metabolism
Anti-Inflammatory Agents
/ pharmacology
Bronchi
/ drug effects
Bronchodilator Agents
/ pharmacology
Cyclic AMP
/ metabolism
Cytokines
/ metabolism
Drug Interactions
Drug Therapy, Combination
Glycopyrrolate
/ pharmacology
Humans
Indans
/ pharmacology
Isometric Contraction
/ drug effects
Mometasone Furoate
/ pharmacology
Quinolones
/ pharmacology
Respiratory Hypersensitivity
/ drug therapy
Airway hyperresponsiveness
Asthma
Inflammation
LABA/ICS
LABA/LAMA/ICS
Synergy
Journal
Pharmacological research
ISSN: 1096-1186
Titre abrégé: Pharmacol Res
Pays: Netherlands
ID NLM: 8907422
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
26
07
2021
revised:
03
08
2021
accepted:
03
08
2021
pubmed:
8
8
2021
medline:
4
3
2022
entrez:
7
8
2021
Statut:
ppublish
Résumé
LABA/ICS and LABA/LAMA/ICS combinations elicit beneficial effects in asthma. Specific evidence concerning the impact of combining indacaterol acetate (IND), glycopyrronium bromide (GLY), and mometasone furoate (MF) on human airway hyperresponsiveness (AHR) and airway inflammation is still missing. The aim of this study was to characterize the synergy of IND/MF and IND/GLY/MF combinations, both once-daily treatments for asthma, in hyperresponsive airways. Passively sensitized human medium and small airways were stimulated by histamine and treated with IND/MF (molar ratio: 100/45, 100/90) and IND/GLY/MF (molar ratio: 100/37/45, 100/37/90). The effect on contractility and airway inflammation was tested. Drug interaction was assessed by Bliss Independence equation and Unified Theory. IND/MF 100/90 elicited middle-to-very strong synergistic relaxation in medium and small airways (+≈20-30% vs. additive effect, P < 0.05), for IND/MF 100/45 the synergy was middle-to-very strong in small airways (+≈20% vs. additive effect, P < 0.05), and additive in medium bronchi (P > 0.05 vs. additive effect). IND/GLY/MF 100/37/45 and 100/37/90 induced very strong synergistic relaxation in medium and small airways (+≈30-50% vs. additive effect, P < 0.05). Synergy was related with significant (P < 0.05) reduction in IL-4, IL-5, IL-6, IL-9, IL-13, TNF-α, TSLP, NKA, SP, and non-neuronal ACh, and enhancement in cAMP. IND/MF and IND/GLY/MF combinations synergistically interact in hyperresponsive medium and small airways and modulate the levels of cytokines, neurokinins, ACh, and intracellular cAMP. The concentrations of MF in the combinations modulate the effects in the target tissue.
Identifiants
pubmed: 34363950
pii: S1043-6618(21)00385-6
doi: 10.1016/j.phrs.2021.105801
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Bronchodilator Agents
0
Cytokines
0
Indans
0
Quinolones
0
Mometasone Furoate
04201GDN4R
indacaterol
8OR09251MQ
Cyclic AMP
E0399OZS9N
Acetylcholine
N9YNS0M02X
Glycopyrrolate
V92SO9WP2I
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
105801Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.